Sign In
Buy IONS
$73.82
+0.85 (+1.16%)
At Close: Jun 03, 2026
Akcea Therapeutics Inc (NASDAQ:AKCA) Major Shareholder Ionis Pharmaceuticals Inc Buys 21,237,715 Shares of Stock
06:00am, Thursday, 15'th Oct 2020
Akcea Therapeutics Inc (NASDAQ:AKCA) major shareholder Ionis Pharmaceuticals Inc acquired 21,237,715 shares of the stock in a transaction that occurred on Saturday, October 10th. The shares were bough
Advisor Group Holdings Inc. Purchases 2,500 Shares of Akcea Therapeutics Inc (NASDAQ:AKCA)
04:14am, Wednesday, 14'th Oct 2020
Advisor Group Holdings Inc. lifted its position in shares of Akcea Therapeutics Inc (NASDAQ:AKCA) by 100.0% during the second quarter, according to the company in its most recent disclosure with the S
Needham Releases a Buy Rating on Ionis Pharmaceuticals (IONS) - Markets
07:05pm, Tuesday, 13'th Oct 2020
In a report released today, Chad Messer from Needham assigned a Buy rating to Ionis Pharmaceuticals (IONS – Research Report),
Akcea Therapeutics Inc (NASDAQ:AKCA) Short Interest Update
02:22am, Monday, 28'th Sep 2020
Akcea Therapeutics Inc (NASDAQ:AKCA) was the target of a large drop in short interest during the month of September. As of September 15th, there was short interest totalling 1,170,000 shares, a drop o
Stanley T. Crooke Sells 2,000 Shares of Ionis Pharmaceuticals Inc (NASDAQ:IONS) Stock
09:52am, Friday, 25'th Sep 2020
Ionis Pharmaceuticals Inc (NASDAQ:IONS) Chairman Stanley T. Crooke sold 2,000 shares of Ionis Pharmaceuticals stock in a transaction on Monday, September 21st. The shares were sold at an average price
American International Group Inc. Sells 285 Shares of Ionis Pharmaceuticals Inc (NASDAQ:IONS)
04:48am, Thursday, 24'th Sep 2020
American International Group Inc. cut its holdings in Ionis Pharmaceuticals Inc (NASDAQ:IONS) by 9.8% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchan
Akcea Therapeutics UK Ltd., a subsidiary of Akcea Therapeutics Inc. (NASDAQ: AKCA), announced today that the National Institute for Health and Care Ex
Bank of America Corp DE Trims Stake in Ionis Pharmaceuticals Inc (NASDAQ:IONS)
06:56am, Wednesday, 16'th Sep 2020
Bank of America Corp DE cut its position in Ionis Pharmaceuticals Inc (NASDAQ:IONS) by 0.7% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchan
Vanguard Group Inc. Boosts Stock Position in Ionis Pharmaceuticals Inc (NASDAQ:IONS)
07:20am, Sunday, 13'th Sep 2020
Vanguard Group Inc. lifted its position in Ionis Pharmaceuticals Inc (NASDAQ:IONS) by 2.1% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Com
Halper Sadeh LLP, a global investor rights law firm, is investigating: Rosetta Stone Inc. (NYSE: RST) concerning potential violations of the federal s
State Board of Administration of Florida Retirement System Buys 839 Shares of Ionis Pharmaceuticals Inc (NASDAQ:IONS)
08:14am, Tuesday, 25'th Aug 2020
State Board of Administration of Florida Retirement System grew its stake in Ionis Pharmaceuticals Inc (NASDAQ:IONS) by 0.5% in the second quarter, HoldingsChannel reports. The fund owned 176,843 shar
Akcea and Ionis to Present Phase 2 Results of AKCEA-APOCIII-L(Rx) in Late-Breaking Presentation at ESC Congress 2020
11:00am, Tuesday, 18'th Aug 2020
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced that data from the Phase 2 study of
Akcea Announces New Pricing and Reimbursement of WAYLIVRA® (volanesorsen) in Germany
11:00am, Thursday, 13'th Aug 2020
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that the German Association of Statutory Sick Funds has agreed upon new pricing and
Cowen Reiterates “Hold” Rating for Akcea Therapeutics (NASDAQ:AKCA)
01:48am, Tuesday, 11'th Aug 2020
Akcea Therapeutics (NASDAQ:AKCA)‘s stock had its “hold” rating reiterated by analysts at Cowen in a research report issued on Sunday, AnalystRatings.com reports. A number of other brokerages hav
